What is MTSL & BioInvest!

Size: px

Start display at page:

Download "What is MTSL & BioInvest!"

Elwin Stone
6 years ago
Views:

1 Biotech Investing Catch The Next Big Wave! John McCamant Editor, Medical Technology Stock Letter What is MTSL & BioInvest! The Medical Technology Stock Letter is your best tool for investing in Biotech stocks Get Educated, Stay Informed and Profit From Biotechnology BioInvest is our one-stop-shop website that answers all of your biotech industry questions, Who & Where is MTSL? MTSL is John McCamant & Jay Silverman Dynamic Biotech Analyst Team Over 50 years analytical experience Two Heads are better than One San Francisco and New York 1

As an equities analyst for the American Healthcare Fund At Burrill& Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund.

2 #1 & #1 Team Up: John McCamant Jay Silverman John McCamant Joined the MTSL as Associate Editor in 1987, named Editor of this leading investment newsletter in August years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund At Burrill& Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch. Jay Silverman Been a biotechnology and pharmaceuticals analyst for over 25 years and has a tremendous track record in analyzing and recommending biotech stocks. Ranked #1 in Biotechnology by The Wall Street Journal s Best on the Street annual analyst survey Frequently quoted in The Wall Street Journal, TIME, Fortune and featured on CNBC and CNN. VP Business Development for Thorne Research from A leading natural products company. VP for Strategic Development for Diversified Natural Products (DNP) from , which merged with Thorne Research in June

3 Re-launched March 2013 Primary Feature: The White Papers Proprietary CEO Insights MTSL archives online for subscribers Comprehensive sector calendar Investment Philosophies laid out Issue by Issue 3

ORAL ARGUMENTS Targeted Super Pills: Wider therapeutic windows allows for better efficacy and safety BIIB's Tecfidera (vs. shots Avonex, Copaxone) CELG's Pomalyst (vs.

4 ORAL ARGUMENTS Targeted Super Pills: Wider therapeutic windows allows for better efficacy and safety BIIB's Tecfidera (vs. shots Avonex, Copaxone) CELG's Pomalyst (vs. IV bendamustine) AMGN's Krypolis (vs. IV bendamustine) INCY's Jakafi (vs. spleenectomy) PCYC's ibrutinib (vs. IV chemotherapy) New and better pills are a major part of the biopharmaceutical revolution MTSL s 2013 ORAL ARGUMENT STOCKS: PCYC, INCY, CNDO PCYC: Ibrutinib poised to be the biggest cancer drug ever INCY: Developing multiple pills for many different targets/diseases CNDO: TSO worm would revolutionize the treatment of autoimmune disease 4

5 THE NEW CLASSES ARE IN SESSION Blockbuster Drug Classes Historical Examples Statins (Lipitor, Crestor, Zocor, etc.) anti-tnf-inhibitors (Remicade, Humira, Enbrel, etc.) THE NEW CLASSES HCV Combinations GILD, ABBV, BMS BTK, PI3K INHIBITORS PCYC, GILD, INFI, TGTX JAK INHIBITORS INCY, PFE, GLPG, ABBV PCSK9 INHIBITORS AMGN, REGN/SNY, ALNY/MDCO BEST IN CLASS OR BUY THE CLASS Ibrutinib is classic example of Best in Class you can often buy several stages of clinical development as programs are de-risked and still generate sound returns What about Buy the Class? More risky but possible when just a few players 5

6 Ibrutinib JAKS OR BETTER INCY: Represents an attractive Buy-The-Class and potential Best-in-Class opportunity PIPELINES 6

Binary Events: How much potential value has already been discounted going into the event?

7 PIPELINES Hit Em Where They Ain t CNDO : TSO worm has huge upside if Phase II is positive NVAX : RSV vaccine opportunity under appreciated BIOTECH RISK MANAGEMENT AN OXYMORON? Binary Events: How much potential value has already been discounted going into the event? ONLY for highest risk appetite Can you buy after the news? Protection options CNDO binary event due Q4 7

8 Risk Management Tools Buy Limits Portfolio Diversification Option Strategies Take Profits/Sell Before The News PLENTIFUL PLATFORMS What makes a good Platform Technology? Patents are Key Management Execution Sangamo s Platform 8

9 Benefits of Platform Companies Partnerships Lower Risk through Diversification Financial Benefits MTSL Platform Companies ALKS long acting anti-psychotics IMGN Mabconjugates INCY small molecule chemistry ISIS antisense NKTR drug delivery NVAX next generation vaccines SGMO 2 nd generation gene therapy CATCH THE NEXT WAVE Biotech is 30 years old (Genentech IPO 1983) Just like it took the tech industry 30 years to get its feet wet Biotech is poised to Deliver on all its promise over the next 25 years Our 50 years of combined experience uniquely position us to provide quality investment advise 9

10 2013 PERFORMANCE OF MTSL UNIVERSE Performance Spread Across Most Stocks No Takeovers To Boost Performance 10

Biotech Sector Analysis: SIDEWAYS SEASONALITY

Biotech Sector Analysis: SIDEWAYS SEASONALITY May 23, 2013 Issue No.755 BTK 1,993.06 NBI 1,892.78 Since Last Issue: BTK: +3.1%; NBI: +1.3%; Model Portfolio: +4.8%; Trader s Portfolio: +4.8% This Issue: ISIS & ASCO UPDATES: ANTH, INCY, NKTR, SGMO Biotech